default author photo

Lara Iglesias

Instituto de Investigación Sanitaria Hospital "12 de Octubre" - Hospital Universitario 12 de Octubre

Madrid

Spain

SCHOLARLY PAPERS

2

DOWNLOADS

61

TOTAL CITATIONS

0

Scholarly Papers (2)

1.

Randomized phase II trial of nivolumab plus paclitaxel in subjects with recurrent/metastatic head and neck squamous cell carcinoma unable for cisplatin-based chemotherapy. NIVOTAX TTCC study

Number of pages: 22 Posted: 15 Jan 2026
Instituto de Investigación Sanitaria Hospital "12 de Octubre" - Hospital Universitario 12 de Octubre, affiliation not provided to SSRN, Hospital Duran i Reynals (ICO) - Catalan Institute of Oncology, affiliation not provided to SSRN, Hospital Clinico San Carlos, affiliation not provided to SSRN, Hospital Duran i Reynals (ICO) - Catalan Institute of Oncology, Hospital Universitario de Navarra, affiliation not provided to SSRN, Hospital Regional Universitario de Málaga, affiliation not provided to SSRN, Hospital Duran i Reynals (ICO) - Catalan Institute of Oncology, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Complejo Hospitalario Universitario de Toledo, affiliation not provided to SSRN, Vall d’Hebron Institute of Oncology (VHIO), Hospital Universitari i Politècnic La Fe, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN and Autonomous University of Barcelona - Medical Oncology Department
Downloads 40 (1,183,237)

Abstract:

Loading...

Head and neck, squamous cell carcinoma, unfit, frail, chemotherapy, immunotherapy

2.

A First-in-Human Phase 1/2 Dose-Escalation Study of Mak683 (Eed Inhibitor) in Patients with Advanced Malignancies

Number of pages: 21 Posted: 09 Oct 2024
Gustave Roussy - Drug Development Department (DITEP), Instituto de Investigación Sanitaria Hospital "12 de Octubre" - Hospital Universitario 12 de Octubre, affiliation not provided to SSRN, The Chinese University of Hong Kong (CUHK), Shizuoka Cancer Center, University of Cologne, University of Toronto - Princess Margaret Cancer Centre, Sarah Cannon Research Institute, affiliation not provided to SSRN, National Cancer Centre Singapore - Division of Medical Oncology, Humanitas University - Department of Biomedical Sciences, affiliation not provided to SSRN, National Hospital Organization Kyushu Cancer Center - Department of Hematology and Cell Therapy, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN and affiliation not provided to SSRN
Downloads 21 (1,448,301)

Abstract:

Loading...

MAK683, EED, PRC2, DLBCL, ES, dose-escalation